Joshua Brody, MD, is the director of the Lymphoma Immunotherapy Program at the Mount Sinai Health System & Tisch Cancer Institute and a faculty member of the Icahn Genomics Institute His clinical focus includes lymphoma, adult non-Hodgkin’s lymphoma, Hodgkin’s disease, Hodgkin’s lymphoma, mantle cell lymphoma, primary central nervous system lymphoma, and leukemia.
Dr. Brody is a faculty member of the Icahn Genomics Institute and a member of the Society for the Immunotherapy of Cancer and the Alliance for Clinical Trials in Oncology. He has developed a clinical program as well as a translational cancer immunotherapy lab that investigates basic and applied tumor immunology for the development of novel therapies, particularly for lymphomas, breast cancer, and head/neck cancer, with results published in journals including Nature Medicine and Cancer Discovery. He has pioneered a therapeutic vaccine approach—in situ vaccination—that induces anti-tumor immunity at the tumor site and can cause regression of tumors throughout the body. He has also developed a way to increase the power of immunotherapy drugs against treatment-resistant lymphomas by combining them with stem cell transplantation. Recently, his group discovered a novel approach to improve immunotherapies by preventing a common escape mechanism that tumors use to evade CAR-T and bispecific antibody therapies.
Dr. Brody is board certified in internal medicine and completed his fellowship in medical oncology at Stanford University. He completed his residency in internal medicine at Yale New Haven Hospital and earned his medical degree at the State University at Stony Brook.